CAMBRIDGE, Mass.--(BUSINESS WIRE)--
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced that, effective immediately, it will begin operating as BIND Therapeutics to reflect the Companys progress in applying its Medicinal Nanoengineering platform to develop a pipeline of highly selective targeted and programmable therapeutics called Accurins. Simultaneous with the name change, the company has launched a new corporate website and URL http://www.BINDTHERAPEUTICS.COM
The new name, BIND Therapeutics, conveys the companys leadership and advancement in developing novel Accurins with unique therapeutic properties by selectively accumulating in diseased tissues and cells, resulting in high drug concentrations at the site of action with low off-target exposure, leading to markedly better efficacy and safety, said Scott Minick, BINDs President and CEO. Our lead product candidate, BIND-014, has completed a Phase 1 clinical study in cancer patients and we are initiating Phase 2 clinical trials in multiple solid tumor types. In addition, we are also developing Accurins in collaboration with pharmaceutical and biotechnology partners including Amgen to enable their promising pipeline candidates to achieve their full potential.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BINDs Medicinal Nanoengineering platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, with the objective of enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes. BIND's lead product candidate, BIND-014, is currently entering Phase 2 clinical testing in cancer patients and is designed to selectively target PSMA, a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at http://www.bindbio.com.
See the article here:
Reflecting Its Growth, BIND Biosciences Changes Name to BIND Therapeutics